Cited by 113AI in cancer detectionBreast Cancer Treatment StudiesRadiomics and Machine Learning in Medical Imaging

Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer

Open access
Li, Fengling, Yang, Yongquan, Wei, Yani, He, Ping, Chen, Jie, Zheng, Zhongxi, Bu, Hong·2021·Journal of Translational Medicine

Abstract

Background: Pathological complete response (pCR) is considered a surrogate endpoint for favorable survival in breast cancer patients treated with neoadjuvant chemotherapy (NAC). Predictive biomarkers of treatment response are crucial for guiding treatment decisions. With the hypothesis that histological information on tumor biopsy images could predict NAC response in breast cancer, we proposed a novel deep learning (DL)-based biomarker that predicts pCR from images of hematoxylin and eosin (H&E)-stained tissue and evaluated its predictive performance. Methods: In total, 540 breast cancer patients receiving standard NAC were enrolled. Based on H&E-stained images, DL methods were employed to automatically identify tumor epithelium and predict pCR by scoring the identified tumor epithelium to produce a histopathological biomarker, the pCR-score. The predictive performance of the pCR-score was assessed and compared with that of conventional biomarkers including stromal tumor-infiltrating lymphocytes (sTILs) and subtype. Results: The pCR-score derived from H&E staining achieved an area under the curve (AUC) of 0.847 in predicting pCR directly, and achieved accuracy, F1 score, and AUC of 0.853, 0.503, and 0.822 processed by the logistic regression method, respectively, higher than either sTILs or subtype; a prediction model of pCR constructed by integrating sTILs, subtype and pCR-score yielded a mean AUC of 0.890, outperforming the baseline sTIL-subtype model by 0.051 (0.839, P = 0.001). Conclusion: The DL-based pCR-score from histological images is predictive of pCR better than sTILs and subtype, and holds the great potentials for a more accurate stratification of patients for NAC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-021-03020-z

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 49 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Li, F., Yang, Y., Wei, Y., He, P., Chen, J., Zheng, Z., & Bu, H.
Affiliations
Sichuan University (CN)
Corresponding author
  • Zheng, Zhongxi
  • Bu, Hong
Venue
Journal of Translational Medicine
Published
2021-08-16
Volume
19
Issue
1
Pages
348-348
ISSN
1479-5876 (ISSN-L)
OpenAlex
W3211240094
Cited by
113
References
49
Citations by year
2026: 20 · 2025: 27 · 2024: 34 · 2023: 20 · 2022: 11 · 2021: 1
FWCI
5.83
Type
journal article
Language
en
Open access
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • 1·3·5 project for disciplines of excellence (ZYGD18012)
  • the Technological Innovation Project of Chengdu New Industrial Technology Research Institute (2017-CY02–00026-GX)
  • the Sichuan Science and Technology Program (2020YFS0088)
  • the 1·3·5 project for disciplines of excellence Clinical Research Incubation Project (2019HXFH036)
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
breast cancer, neoadjuvant chemotherapy, pathological complete response, predictive biomarkers, deep learning, stromal tumor-infiltrating lymphocytes, tumor subtypes, treatment response prediction, patient stratification
MeSH terms
Deep Learning, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Biomarkers, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review